References

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Assessing the Global Burden of Type 2 Diabetes in Women of Reproductive Age

10.1371/journal.pone.0322787 · 2025 · External reference

The Effect of Obesity on Fertility: A Systematic Review

10.1016/j.semerg.2025.102670 · 2026 · External reference

The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity: A Systematic Review and Meta‐Analysis

10.7326/annals-24-01025 · 2025 · External reference

Risk of Major Congenital Malformations in Relation to Maternal Overweight and Obesity Severity: Cohort Study of 1.2 Million Singletons

10.1136/bmj.j2563 · 2017 · External reference

Periconception Glycemic Control and Congenital Anomalies in Women With Pregestational Diabetes

10.1136/bmjdrc-2020-001966 · 2021 · External reference

Fetal and Perinatal Consequences of Maternal Obesity

10.1136/adc.2009.170928 · 2011 · External reference

Effectiveness of Behavioural Weight Loss Interventions Delivered in a Primary Care Setting: A Systematic Review and Meta‐Analysis

10.1093/fampra/cmu064 · 2014 · External reference

Pregnancy After Metabolic Bariatric Surgery: Risks and Rewards for Mother and Child

10.1111/1471-0528.18032 · 2025 · External reference

Bariatric Surgery, Gestational Diabetes and Perinatal Outcomes: A Population‐Based Study

10.1111/1471-0528.70226 · 2026 · External reference

Adverse Pregnancy Outcomes Among Mothers With Hypertensive Disorders in Pregnancy: A Meta‐Analysis of Cohort Studies

10.1016/j.preghy.2021.03.001 · 2021 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Effects of GLP‐1 Agonists and SGLT2 Inhibitors During Pregnancy and Lactation on Offspring Outcomes: A Systematic Review of the Evidence

10.3389/fendo.2023.1215356 · 2023 · External reference

Evaluation of GLP‐1 Receptor Agonists in Obstetrics and Perinatal Outcomes: A Systematic Review and Meta‐Analysis

10.1016/j.jogoh.2025.103046 · 2025 · External reference

Prescribing Trends in Glucagon‐Like Peptide‐1 Medications Among Pregnant and Postpartum Persons

10.1097/aog.0000000000006161 · 2026 · External reference

Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists' Use During Pregnancy: Safety Data From Regulatory Clinical Trials

10.1111/dom.16437 · 2025 · External reference

Incidence of GLP‐1 Receptor Agonist Use by Women of Reproductive Age Attending General Practices in Australia, 2011‐2022: A Retrospective Open Cohort Study

10.5694/mja2.70026 · 2025 · External reference

Mechanisms of GLP‐1 Receptor Agonist‐Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation

10.1016/j.amjmed.2025.01.021 · 2025 · External reference

Gastric Inhibitory Polypeptide: The Neglected Incretin Revisited

10.1016/s0167-0115(02)00039-3 · 2002 · External reference

Glucagon‐Like Peptide‐1 7‐36: A Physiological Incretin in Man

10.1016/s0140-6736(87)91194-9 · 1987 · External reference

The Physiology of Glucagon‐Like Peptide 1

10.1152/physrev.00034.2006 · 2007 · External reference

Glucagon‐Like Peptide‐1 Cells in the Gastrointestinal Tract and Pancreas of Rat, Pig and Man

10.1111/j.1365-2362.1992.tb01464.x · 1992 · External reference

Cellular Localization of Gastric Inhibitory Polypeptide in the Duodenum and Jejunum

10.1136/gut.14.4.284 · 1973 · External reference

Mechanisms Underlying the Rapid Degradation and Elimination of the Incretin Hormones GLP‐1 and GIP

10.1016/j.beem.2009.03.005 · 2009 · External reference

GIP and GLP‐1, the Two Incretin Hormones: Similarities and Differences

10.1111/j.2040-1124.2010.00022.x · 2010 · External reference

Biological Effects and Metabolic Rates of Glucagonlike Peptide‐1 7‐36 Amide and Glucagonlike Peptide‐1 7‐37 in Healthy Subjects Are Indistinguishable

10.2337/diab.42.5.658 · 1993 · External reference

Central Administration of GLP‐1‐(7‐36) Amide Inhibits Food and Water Intake in Rats

1996 · External reference

Truncated GLP‐1 (Proglucagon 78‐107‐Amide) Inhibits Gastric and Pancreatic Functions in Man

10.1007/bf01316798 · 1993 · External reference

Effects of GLP‐1 on Gastric Emptying, Antropyloric Motility, and Transpyloric Flow in Response to a Nonnutrient Liquid

10.1023/a:1018863716749 · 1998 · External reference

Neuronal Control of Energy Homeostasis

10.1016/j.febslet.2007.11.063 · 2008 · External reference

Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs

10.2337/diabetes.50.7.1588 · 2001 · External reference

Secretion, Degradation, and Elimination of Glucagon‐Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients With Chronic Renal Insufficiency and Healthy Control Subjects

10.2337/diabetes.53.3.654 · 2004 · External reference

Glucagon‐Like Peptide‐1 Receptor: Mechanisms and Advances in Therapy

10.1038/s41392-024-01931-z · 2024 · External reference

Unresolved reference

External reference

Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes

10.1056/nejmoa2307563 · 2023 · External reference

Long‐Term Kidney Outcomes of Semaglutide in Obesity and Cardiovascular Disease in the SELECT Trial

10.1038/s41591-024-03015-5 · 2024 · External reference

Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Obesity

10.1056/nejmoa2306963 · 2023 · External reference

GLP‐1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

10.1161/circulationaha.122.059595 · 2022 · External reference

The Cardiovascular Biology of Glucagon‐Like Peptide‐1

10.1016/j.cmet.2016.06.009 · 2016 · External reference

Glucagon‐Like Receptor Agonists and Next‐Generation Incretin‐Based Medications: Metabolic, Cardiovascular, and Renal Benefits

10.1016/s0140-6736(25)02105-1 · 2026 · External reference

Drug Transfer and Metabolism by the Human Placenta

10.2165/00003088-200443080-00001 · 2004 · External reference

GLP‐1‐Mediated Pregnancy and Neonatal Complications in Mice

10.3390/jdb13030029 · 2025 · External reference

Maternal GLP‐1 Receptor Activation Inhibits Fetal Growth

10.1152/ajpendo.00361.2023 · 2024 · External reference

Inflammation‐Induced Adverse Pregnancy and Neonatal Outcomes Can be Improved by the Immunomodulatory Peptide Exendin‐4

10.3389/fimmu.2018.01291 · 2018 · External reference

Long‐Term Functional Alterations Following Prenatal GLP‐1R Activation

10.1016/j.ntt.2021.106984 · 2021 · External reference

The Challenges of Obesity for Fertility: A FIGO Literature Review

10.1002/ijgo.14538 · 2023 · External reference

Obesity and Female Reproductive Health; Is There a Role for Glucagon‐Like Peptide‐1 Receptor Agonists?

10.1111/obr.70015 · 2026 · External reference

Female Obesity and Infertility

10.1016/j.bpobgyn.2014.10.014 · 2015 · External reference

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP‐1 Receptor Agonists

10.1210/clinem/dgaa285 · 2020 · External reference

Association Between Body Mass Index, Weight Loss and the Chance of Pregnancy in Women With Polycystic Ovary Syndrome and Overweight or Obesity: A Retrospective Cohort Study in the UK

10.1093/humrep/deac267 · 2023 · External reference

Efficacy of Exenatide on Weight Loss, Metabolic Parameters and Pregnancy in Overweight/Obese Polycystic Ovary Syndrome

10.1111/cen.13454 · 2017 · External reference

Liraglutide Increases IVF Pregnancy Rates in Obese PCOS Women With Poor Response to First‐Line Reproductive Treatments: A Pilot Randomized Study

10.1530/eje-18-0175 · 2018 · External reference

Glucagon‐Like Peptide‐1 Receptor Agonists Among Pregnancies With Pregestational Diabetes and Its Relationship With Congenital Malformations

2025 · External reference

Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonist Use During the First Trimester in Pregnant Women With Type 2 Diabetes

10.1016/j.amjcard.2025.03.013 · 2025 · External reference

Safety of GLP‐1 Receptor Agonists and Other Second‐Line Antidiabetics in Early Pregnancy

10.1001/jamainternmed.2023.6663 · 2024 · External reference

Use of GLP1 Receptor Agonists in Early Pregnancy and Reproductive Safety: A Multicentre, Observational, Prospective Cohort Study Based on the Databases of Six Teratology Information Services

10.1136/bmjopen-2023-083550 · 2024 · External reference

Unintentional Periconceptional Exposure to Glucagon‐Like Peptide‐1 Receptor Agonists and Adverse Pregnancy Outcomes: A Nationwide Cohort Study in Taiwan

10.1111/dom.70334 · 2026 · External reference

Pregnancy Outcomes After Semaglutide Exposure

10.1111/bcpt.70021 · 2025 · External reference

Physiological Changes and Cardiovascular Investigations in Pregnancy

10.1016/j.hlc.2020.10.001 · 2021 · External reference

Gestational Weight Gain and Pregnancy Outcomes After GLP‐1 Receptor Agonist Discontinuation

10.1001/jama.2025.20951 · 2025 · External reference

The Safety Profile of Usage of Glucagon‐Like Peptide‐1 Receptor Agonists in Pregnancy: A Pharmacovigilance Analysis Based on the Food and Drug Administration Adverse Event Reporting System

10.1111/bcp.16354 · 2025 · External reference

Gestational Weight Gain and Hypertensive Disorders of Pregnancy With Prepregnancy and Early Pregnancy Glucagon‐Like Peptide‐1 Receptor Agonist Exposure

10.1097/aog.0000000000005995 · 2025 · External reference

Preconception Glucagon‐Like Peptide‐1 Receptor Agonist Use Associated With Decreased Risk of Adverse Obstetrical Outcomes

10.1016/j.ajog.2025.01.019 · 2025 · External reference

Periconceptional GLP‐1 Receptor Agonist Exposure and Obstetric Outcomes: A Danish Nationwide Cohort Study

10.1093/hropen/hoag015 · 2026 · External reference

10.1038/s41366‐026‐02111‐5

10.1038/s41366‐026‐02111‐5 · External reference

Prepregnancy GLP‐1RA Exposure and Risk of Hypertensive Disorders of Pregnancy Among Women With Obesity and Diabetes

10.1002/oby.70221 · 2026 · External reference

Congenital Malformation Risk According to Hemoglobin A1c Values in a Contemporary Cohort With Pregestational Diabetes

10.1055/s-0041-1730435 · 2021 · External reference

Estimating Global Burden of Disease due to Congenital Anomaly: An Analysis of European Data

10.1136/archdischild-2016-311845 · 2018 · External reference

GLP‐1 Receptor Agonist Exposure During Pregnancy: A Systematic Review and Meta‐Analysis of Adverse Pregnancy Outcomes

2026 · External reference

Pregnancy Outcomes Following First Trimester Exposure to Semaglutide

10.1177/1753495x251346330 · 2025 · External reference

Case Report: Exenatide Use During Pregnancy

10.1097/ten.0b013e3181a5875e · 2009 · External reference

Normal Pregnancy Outcome After First‐Trimester Exposure to Liraglutide in a Woman With Type 2 Diabetes

10.1111/dme.12726 · 2015 · External reference

Pregnancy Outcome and Liraglutide Levels in Serum and Umbilical Vein Blood of a Woman With Type 2 Diabetes. A Case Report

2018 · External reference

Semaglutide and Pregnancy

10.1002/ijgo.15092 · 2023 · External reference

Case Series: Exposure to Glucagon‐Like Peptide‐1 Receptor Agonist in the First Trimester of Pregnancy in Two Siblings

10.2174/0118715303252109231023115112 · 2024 · External reference

A Case Report on Use of Dulaglutide During the First Weeks of Pregnancy in Woman Affected by Type 2 Diabetes Mellitus

10.1007/s00592-022-01954-4 · 2023 · External reference

Gestational Weight Gain: Update on Outcomes and Interventions

10.1007/s11892-020-1296-1 · 2020 · External reference

Pre‐Pregnancy GLP‐1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry‐Over Versus Post‐Discontinuation Metabolic Rebound in a Multinational Federated Cohort

10.1111/dom.70853 · 2026 · External reference

Gestational Weight Gain Particularly Affects the Risk of Large for Gestational Age Infants in Non‐Obese Mothers

10.1055/a-0891-0919 · 2019 · External reference

The Impact of Gestational Weight Gain on Fetal and Neonatal Outcomes: The Araraquara Cohort Study

10.1186/s12884-024-06523-x · 2024 · External reference

Nutritional Deficiencies and Muscle Loss in Adults With Type 2 Diabetes Using GLP‐1 Receptor Agonists: A Retrospective Observational Study

10.1016/j.obpill.2025.100186 · 2025 · External reference

The Effect of Semaglutide on Intestinal Iron Absorption in Patients With Type 2 Diabetes Mellitus—A Pilot Study

10.1111/dom.16368 · 2025 · External reference

Investigating Nutrient Intake During Use of Glucagon‐Like Peptide‐1 Receptor Agonist: A Cross‐Sectional Study

10.3389/fnut.2025.1566498 · 2025 · External reference

Unresolved reference

External reference

Pharmacologically Relevant Drug Interactions of Glucagon‐Like Peptide‐1 Receptor Agonists

10.15406/japlr.2019.08.00311 · 2019 · External reference

Unresolved reference

External reference

Subcutaneous Semaglutide During Breastfeeding: Infant Safety Regarding Drug Transfer Into Human Milk

10.3390/nu16172886 · 2024 · External reference

Unresolved reference

External reference

10.2139/ssrn.5387250

10.2139/ssrn.5387250 · External reference

An Overview of Links Between Obesity and Mental Health

10.1007/s13679-015-0164-9 · 2015 · External reference

Prevalence of Use and Interest in Using Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Loss: A Population Study in Great Britain

10.1186/s12916-025-04528-7 · 2026 · External reference

Maternal Mental Health During Pregnancy: A Critical Review

2022 · External reference

Weight Regain After Cessation of Medication for Weight Management: Systematic Review and Meta‐Analysis

10.1136/bmj-2025-085304 · 2026 · External reference

Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension

10.1111/dom.14725 · 2022 · External reference

Unresolved reference

External reference

Unresolved reference

External reference